Surgery Was the Only Way to Diagnose Endometriosis. Australia Just Changed That

A Perth company just signed its endometriosis blood test into 2,000 collection centres. Australia spent eight years and A$792.9 million making that possible.

Australia was the first country in the world to write a national action plan for endometriosis.

Eight years and A$792.9 million later, Australian women still wait an average of seven years for a diagnosis, according to the federal Department of Health.

The distance between them is the most useful thing in women's health policy right now, and on Wednesday a small Perth diagnostics company showed why.

Start with the plan.

In 2018, Australia's health minister stood in Parliament and apologized to women with endometriosis for what he called the historic failures of the country's medical system. The National Action Plan for Endometriosis that followed was the first of its kind anywhere.

The UK, Canada and France have since built their own versions on Australia's template, and inside Australia it triggered 23 further national action plans for other conditions, per the Medical Journal of Australia's InSight+.

Then it grew teeth. The 2025-26 federal budget committed A$792.9 million to women's health, framed not as wellness but as cost-of-living relief. Yaz and Yasmin became the first new contraceptive pills added to the Pharmaceutical Benefits Scheme in more than 30 years. Estrogel, Prometrium and Estrogel Pro became the first new menopause therapies subsidized in over 20. Medicare started paying for dedicated menopause assessments, and for 45-minute gynecology consultations on complex conditions.

The Department of Health has published results as they've come in. More than 800,000 women have filled over 3 million discounted prescriptions. More than 125,000 have taken a Medicare-funded menopause assessment.

And on July 1, all 33 of the country's endometriosis and pelvic pain clinics began providing menopause and perimenopause care.

When we wrote about Taiwan, the country ranked first in the world for women's health, we called midlife hormonal care an open field no nation had claimed. Australia claimed it three weeks ago.

So the machinery works.

And none of it moved the seven-year number.

It couldn't. Diagnostic delay in endometriosis was never a funding problem.

The disease is still confirmed by laparoscopy, surgery under general anesthesia, and imaging misses superficial lesions, so a clean scan rules nothing out and women get parked in watchful waiting. Governments can pay for a test. They can't invent one.

Which brings us to Wednesday.

Proteomics International, a Perth company carrying a market capitalization near A$29 million, told the ASX it had signed a three-year exclusive national distribution agreement with Healius, one of Australia's largest pathology networks, with an option for three more years. The deal puts its Promarker blood-test portfolio into more than 2,000 patient collection centres. Proteomics keeps the laboratory testing and clinical reporting. Healius takes specimen collection, referrer engagement and market access. Rollout runs through the 2027 financial year, and the company said plainly that revenue can't be reliably estimated yet.

That portfolio includes PromarkerEndo, a ten-protein blood panel for endometriosis. Results published in Human Reproduction showed it detecting severe disease with 99.7% accuracy and early-stage disease above 85%. External validation presented at the World Congress on Endometriosis showed 83% sensitivity and 95% specificity across 436 cases. Two weeks earlier, on July 8, the US Patent and Trademark Office granted the company's endometriosis biomarker patent, with protection running to March 2041.

So a company worth under A$30 million locked intellectual property in the world's largest healthcare market, then a fortnight later locked distribution in one of its smallest.

Market access is the hardest problem in clinical women's health. Not the science. American companies assemble access one employer contract at a time, which is roughly what Midi Health's $100 million round funds, scaling delivery of care that already exists.

Australia assembled it as public policy. Medicare items that pay a clinician to spend 45 minutes on a complex gynecological case. Thirty-three specialist clinics concentrating the symptomatic population. Years of national awareness campaigns telling women their pain is real and worth investigating. One payer that has already said yes to women's health as a line in the budget.

That's the return on eight years. Not a shorter wait, which was never in the plan's power, but a market with the friction taken out of it.

When the instrument finally showed up, the company carrying it didn't have to build a collection network, teach a referral base what endometriosis is, or argue that the condition warrants looking for.

Metluma's 2026 Australian Menopause Experience Report, drawn from 1,468 women using a clinical assessment tool built with Monash University, found 43% triggered at least one red flag requiring referral within 48 hours of baseline screening, and that menopause stage predicted symptoms better than age did. That's triage-grade evidence, generated by a private company working inside a system that funnels women toward care.

None of this makes Australia a big market. Thirteen million women, and Proteomics will need the United States for scale, which is exactly why it filed there first. But launch markets get chosen on friction, not size, and Australia spent eight years and A$792.9 million removing friction.

The world's first endometriosis plan couldn't fix its worst number.

But it built the market for the thing that might.